When I began working in oncology more than 20 years ago, patients diagnosed with advanced bladder cancer—particularly those whose disease had spread beyond the bladder—often faced a very grim prognosis. Treatment options were largely restricted to chemotherapy, and while initial responses could occur, they were frequently short-lived. Long-term survival was uncommon.
Over the past 10 to 15 years, however, advances in cancer treatment have significantly changed this outlook. Let’s discuss some of the more prevalent advancements that have changed the landscape of treating bladder cancer.
Immunotherapy: A Major Breakthrough
One of the most important developments has been the introduction of immunotherapy, which helps the immune system recognize and attack cancer cells.
Like many cancers, Bladder cancer can manipulate our immune system, so it is not able to recognize the cancer cells as a danger. Modern immunotherapy drugs, called immune checkpoint inhibitors, work by removing the disguise placed by the cancer cells. This allows our immune cells to identify and destroy cancer cells more effectively.
While metastatic bladder cancer still carries a poor overall prognosis—with approximately 9% 5-year survival in distant-stage disease—these newer therapies have extended survival for many patients. (1) In fact, patients with disease that is contained within the bladder or spread to nearby organs and lymph nodes have 5-year survival rates 4-10x greater! (1)
Antibody–Drug Conjugates: Targeted “Smart Chemotherapy”
Another major innovation is the development of antibody–drug conjugates (ADCs). These medications are made up of 2 components. First, there is a targeted antibody that binds cancer cells. Once attached, a potent chemotherapy agent is delivered directly inside the tumor.
The binding nature of these medications ensures the powerful chemotherapy is targeted right at the cancer cells, causing less damage to surrounding healthy tissue. While every patient is different, less damage to healthy cells means fewer side effects.
Clinical use has shown that ADCs can produce meaningful tumor shrinkage even after other treatments fail This is a major advance in later-line therapy. (2)
Combination Therapy: A New Era
Across the cancer treatment landscape, combination therapies are prevalent in most every disease state. Incorporating the latest immunotherapies, ADCs, surgical technologies, along with advanced molecular testing, radiation, and traditional chemotherapies have shown improved response rates, faster tumor shrinkage, and longer disease control.
For example, a recent study conducted at the NYU Grossman School of Medicine in New York published just last month studied the combination of immunotherapy with chemoradiation in bladder cancer. This study demonstrated 83% overall survival at 2 years and approximately 60% bladder-intact disease-free survival at 2-years. (3)
This is a significant study in that it demonstrates both a high survival rate and being able to preserve a functioning bladder.
Bladder Preservation vs. Removal: Then vs. Now
In addition to the advancements in medicinal treatments, there has been progress made in the surgical and radiation treatments available. This has led to higher rates of bladder preservation, while still producing longer cancer free survival. Let’s start by discussing standard treatments from just a decade. Ago. First, radical cystectomy (complete bladder removal) was the standard for muscle-invasive disease. There were few other options available. 5-year survival after surgery was approximately 50–55%. (4)
Today, treatment is more personalized, with increasing use of bladder-preserving strategies. These methods include Trimodality therapy (tumor resection + chemotherapy + radiation). This multifaceted approach has shown improving results in both survival as well as organ preservation. The addition of the Immunotherapy-based regimens discussed above have provided options for patients and their physicians to choose a path which best meets their needs and condition. Bladder preservation strategies such as trimodality therapy can achieve overall survival rates comparable to radical cystectomy, with no statistically significant difference in long-term outcomes in well-selected patients (4)
Collectively, the studies discussed in the last 2 sections show that selected patients can now preserve their bladder without compromising survival, representing a major shift from historical treatment paradigms focused primarily on surgical removal.
Surgical Advancements
Surgical treatment has also improved significantly. Robot-assisted surgery which was in it’s infancy at the start of my career is now widely available in both the community and academic hospital settings. This minimally invasive technique has similar outcomes when compared to open surgery (5). But robot-assisted surgery also provides a number of benefits to our patients. First, there are significantly fewer complications including reduced blood clots and infections. Second, there is a faster recovery process. These two factors combine to promote an improved postoperative quality of life.
Looking Ahead
Although not all patients respond the same way, the progress in advanced bladder cancer treatment has been substantial. Today, more patients are living for years after diagnosis. Many can maintain normal activity levels. Early detection and these advanced treatments are helping many achieve long-term disease control or remission. In summary, Advanced bladder cancer is no longer universally considered a rapidly fatal condition.
With all the progress that has been made, ongoing research continues to expand treatment options. Currently, there are new immunotherapy combinations under investigation. Numerous targeted therapies are at various stages of clinical trials and advancing genetic testing is allowing for biomarker-driven care that can provide individualized care plans that allow select-patients both disease survival as well as bladder preservation.
We are proud at Northwest Cancer Centers to contribute to these advancements through participation in national clinical trials, helping ensure patients have access to the latest therapies and improved outcomes.